Table 1.
Characteristics | MRONJ Patients n = 63 |
---|---|
Age (years) (mean ± SD) * | 69.33 ± 11.06 |
Sex | |
Female | 46 |
Male | 17 |
Duration of treatment (months) (mean ± SD) * | 46.42 ± 39.77 |
Disorder * | |
Breast cancer | 26 |
Prostate cancer | 11 |
Myeloma multiplex | 11 |
Osteoporosis | 7 |
Lung cancer | 2 |
Melanoma malignum | 1 |
Colon cancer | 1 |
Cervical cancer | 1 |
Chemotherapy * | |
Yes | 38 |
No | 22 |
Hormone deprivation therapy | |
Yes | 32 |
No | 28 |
Antiresorptive agent *, ** | |
Alendronate (p.o.) | 1 |
Ibandronate (p.o.) | 4 |
Risedronate (p.o.) | 1 |
Zoledronate (iv./inj.) | 29 |
Denosumab (inj.) | 29 |
MRONJ localization *, *** | |
Maxilla | 19 |
Mandibula | 42 |
MRONJ stage *, **** | |
1 | 1 |
2 | 44 |
3 | 15 |
* There were no available clinical data for three patients. ** Four patients had both bisphosphonate and denosumab. *** One patient had both maxillar and mandibular involvement. **** Based on the American Association of Oral and Maxillofacial Surgeons’(AAOMS) Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 update.